| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Trader-Interview mit Sascha Huber: Marvell Technology, Intuit, Salesforce, Tempus AI & MicroStrategy | 626 | LS-X Trader | In dieser Ausgabe des Trader-Interviews analysieren Andreas Bernstein und Sascha Huber die aktuelle Börsenlage und beleuchten ausgewählte Einzelwerte mit Fokus auf den Einfluss von Künstlicher Intelligenz... ► Artikel lesen | |
| Mo | Neurocrine Biosciences: Milliarden-Kauf von Soleno Therapeutics? | 619 | sharedeals.de | Die Biotechnologiebranche könnte vor der nächsten milliardenschweren Übernahme stehen. Der US-Pharmakonzern Neurocrine Biosciences befindet sich laut einem Bericht der Financial Times in fortgeschrittenen... ► Artikel lesen | |
| Mo | SCINAI IMMUNOTHERAPEUTICS LTD: Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities | 454 | PR Newswire | JERUSALEM, April 6, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI); ("Scinai" or the "Company"), a biopharmaceutical company developing inflammation... ► Artikel lesen | |
| Mo | Neurocrine Biosciences, Inc.: Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio | 363 | PR Newswire | VYKAT XR (diazoxide choline) is the First and Only FDA Approved Treatment for Hyperphagia in Prader-Willi Syndrome and Represents a Transformative Therapy
Expands... ► Artikel lesen | |
| 00:02 | Moderna, Inc.: Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 | 325 | ACCESS Newswire | CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010... ► Artikel lesen | |
| Mo | BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer | 312 | GlobeNewswire (Europe) | - Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval - RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst... ► Artikel lesen | |
| Mo | Amgen: Phase 3 Trial Of TEPEZZA Meets Primary And Key Secondary Endpoints | 306 | AFX News | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced positive topline results from a Phase 3 trial of TEPEZZA administered by subcutaneous injection via an on-body injector in participants with... ► Artikel lesen | |
| Mo | Reportable, Inc.: Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25 | 295 | Newsfile | Dallas, Texas--(Newsfile Corp. - April 6, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's 4Q25 update continues... ► Artikel lesen | |
| Mo | Neurocrine To Acquire Soleno For $2.9 Bln Cash Deal; Soleno Stock Surges In Pre-market | 288 | AFX News | WASHINGTON (dpa-AFX) - Neurocrine Biosciences, Inc. (NBIX), on Monday, said it has entered into a definitive agreement to acquire Soleno Therapeutics, Inc. (SLNO) for $53 per share in cash,... ► Artikel lesen | |
| Mo | Rapid Dose Therapeutics Corp.: Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt | 286 | Newsfile | Burlington, Ontario--(Newsfile Corp. - April 6, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company") announced today that pursuant to the terms of its amended... ► Artikel lesen | |
| Mo | Quantum-Si Incorporated: Quantum-Si Announces the Start of the Proteus Roadshow | 285 | Business Wire | Multi-city Roadshow To Drive Awareness of Proteus and Develop Customer Funnel for Commercial Launch Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics... ► Artikel lesen | |
| Mo | Kraig Biocraft Laboratories Shatters Production Record, Delivering Over 1.3 Metric Tons of Spider Silk Cocoons in a Single Month, A 5X Increase Over Previous High | 280 | GlobeNewswire (Europe) | ANN ARBOR, Mich., April 06, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced... ► Artikel lesen | |
| Mo | Revelation Biosciences, Inc.: Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board | 220 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / April 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to... ► Artikel lesen | |
| Mo | IDEAYA Biosciences, Inc.: IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer | 157 | PR Newswire | Potential first-in-class and selective equipotent dual inhibitor of KAT6/7 with single-digit to low teens nano-molar cellular potency in target engagement assays... ► Artikel lesen |
| Unternehmen / Aktien | Kurs | Dividende 12M | Div.-Rendite | Erw. Dividende | Erw. Ex.-Datum | |
|---|---|---|---|---|---|---|
| BB BIOTECH | 47,850 | 2,47 | +5,16 % | 2,25 | 23.03.2026 | |
| CSL | 84,23 | 2,61 | +3,10 % | 1,84 | 10.03.2026 | |
| AMGEN | 301,50 | 8,38 | +2,78 % | 2,52 | 15.05.2026 | |
| RECORDATI | 48,620 | 1,30 | +2,67 % | 0,71 | 18.05.2026 | |
| NOVONESIS | 51,64 | 0,87 | +1,68 % | 4,25 | 20.03.2026 | |
| SINO BIOPHARM | 0,698 | 0,01 | +1,43 % | 0,05 | 24.06.2026 | |
| GENUS | 27,600 | 0,38 | +1,38 % | 0,11 | 05.03.2026 | |
| VITROLIFE | 8,630 | 0,10 | +1,16 % | 1,10 | 06.05.2026 | |
| 3SBIO | 2,740 | 0,03 | +1,09 % | 0,25 | 21.07.2026 | |
| BIOMERIEUX | 92,60 | 0,90 | +0,97 % | 0,98 | 09.06.2026 |